Haleon plc (HLN)vsLiquidia Technologies Inc (LQDA)
HLN
Haleon plc
$9.11
-2.04%
HEALTHCARE · Cap: $40.43B
LQDA
Liquidia Technologies Inc
$42.30
+0.05%
HEALTHCARE · Cap: $3.76B
Smart Verdict
WallStSmart Research — data-driven comparison
Haleon plc generates 6867% more annual revenue ($11.03B vs $158.32M). HLN leads profitability with a 15.1% profit margin vs -43.5%. HLN earns a higher WallStSmart Score of 63/100 (C+).
HLN
Buy63
out of 100
Grade: C+
LQDA
Hold38
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-22.4%
Fair Value
$9.12
Current Price
$9.11
$0.01 premium
Intrinsic value data unavailable for LQDA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 92.0% YoY
Reasonable price relative to book value
Strong operational efficiency at 23.2%
Generating 1.3B in free cash flow
Revenue surging 3055.0% year-over-year
Strong operational efficiency at 21.5%
Areas to Watch
Expensive relative to growth rate
0.6% revenue growth
0.0% earnings growth
Trading at 82.9x book value
ROE of -111.1% — below average capital efficiency
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : HLN
The strongest argument for HLN centers on EPS Growth, Price/Book, Operating Margin. Profitability is solid with margins at 15.1% and operating margin at 23.2%.
Bull Case : LQDA
The strongest argument for LQDA centers on Revenue Growth, Operating Margin. Revenue growth of 3055.0% demonstrates continued momentum.
Bear Case : HLN
The primary concerns for HLN are PEG Ratio, Revenue Growth.
Bear Case : LQDA
The primary concerns for LQDA are EPS Growth, Price/Book, Return on Equity.
Key Dynamics to Monitor
HLN profiles as a value stock while LQDA is a hypergrowth play — different risk/reward profiles.
LQDA carries more volatility with a beta of 0.42 — expect wider price swings.
LQDA is growing revenue faster at 3055.0% — sustainability is the question.
HLN generates stronger free cash flow (1.3B), providing more financial flexibility.
Bottom Line
HLN scores higher overall (63/100 vs 38/100), backed by strong 15.1% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Haleon plc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Haleon plc (HLN) is a prominent global player in the consumer health sector, dedicated to providing innovative health solutions through its diverse portfolio, which includes renowned brands like Sensodyne, Panadol, and Voltaren. Established as a spin-off from GlaxoSmithKline, the company leverages its strong brand equity to cater to critical health segments such as oral care, pain relief, and dietary supplements. Committed to sustainability and consumer-centric innovation, Haleon is strategically positioned to enhance health outcomes worldwide while pursuing growth and generating value for its shareholders through targeted investments and continuous product development.
Visit Website →Liquidia Technologies Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and markets various products for the unmet needs of patients in the United States. The company is headquartered in Morrisville, North Carolina.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?